Abstract
The endocannabinoid system has been involved in the control of several neurophysiological and behavioural responses. Indeed, recent studies have suggested that the cannabinoid system could represent an important substrate for the control of emotional behaviour, and further research would probably help to identify new promising therapeutic targets. This paper reviews the results obtained in different animal models used to investigate emotional states after the manipulation of the endocannabinoid system. Cannabinoid compounds can induce anxiogenic- and anxiolytic-like responses in rodents depending on the experimental conditions. Studies using knockout mice lacking the CB1 cannabinoid receptors have shown the participation of this receptor in several behavioural responses including anxiety- and depressive-like states. Furthermore, the endocannabinoid system regulates the hypothalamic-pituitary adrenal axis, which is involved in providing an appropriate response to stressful situations. Recent studies have also demonstrated that the endocannabinoids can function as retrograde messengers, modulating the release of different neurotransmitter, including opioids, GABA and cholecystokinin that have been classically involved in the control of anxiety-like responses. All this recent information has further clarified the role played by the endogenous cannabinoid system in the control of emotional behaviour and provides data to support a new possible therapeutic use of cannabinoid compounds.
Keywords: cannabinoids, cb cannabinoid receptors, knockout mice, emotional-like behaviour, anxiety-like responses, hypothalamic-pituitary-adrenal axis, elevated plus maze, lit-dark box, gaba
Current Pharmaceutical Design
Title: Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour
Volume: 11 Issue: 26
Author(s): O. Valverde
Affiliation:
Keywords: cannabinoids, cb cannabinoid receptors, knockout mice, emotional-like behaviour, anxiety-like responses, hypothalamic-pituitary-adrenal axis, elevated plus maze, lit-dark box, gaba
Abstract: The endocannabinoid system has been involved in the control of several neurophysiological and behavioural responses. Indeed, recent studies have suggested that the cannabinoid system could represent an important substrate for the control of emotional behaviour, and further research would probably help to identify new promising therapeutic targets. This paper reviews the results obtained in different animal models used to investigate emotional states after the manipulation of the endocannabinoid system. Cannabinoid compounds can induce anxiogenic- and anxiolytic-like responses in rodents depending on the experimental conditions. Studies using knockout mice lacking the CB1 cannabinoid receptors have shown the participation of this receptor in several behavioural responses including anxiety- and depressive-like states. Furthermore, the endocannabinoid system regulates the hypothalamic-pituitary adrenal axis, which is involved in providing an appropriate response to stressful situations. Recent studies have also demonstrated that the endocannabinoids can function as retrograde messengers, modulating the release of different neurotransmitter, including opioids, GABA and cholecystokinin that have been classically involved in the control of anxiety-like responses. All this recent information has further clarified the role played by the endogenous cannabinoid system in the control of emotional behaviour and provides data to support a new possible therapeutic use of cannabinoid compounds.
Export Options
About this article
Cite this article as:
Valverde O., Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour, Current Pharmaceutical Design 2005; 11 (26) . https://dx.doi.org/10.2174/138161205774370780
DOI https://dx.doi.org/10.2174/138161205774370780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Autonomic Responses After Isometric Training at Different Intensities on Obese People
Current Hypertension Reviews Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Alpha-2 Agonists: Can they Modify the Outcomes in the Postanesthesia Care Unit?
Current Drug Targets Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety Effect of Non-Vegetarian Diet on Cardiovascular Reactivity to Mental Stress in Young Adults
Vascular Disease Prevention (Discontinued) Atypical Presentation Of Anti-Retroviral Therapy Induced Lactic Acidosis as Acute Right Ventricular Failure And Severe Pulmonary Hypertension
New Emirates Medical Journal Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Synthesis of Dihydropyridines: Patented Catalysts and Biological Applications
Recent Patents on Catalysis (Discontinued) Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders
Current Medicinal Chemistry When and How Should We Cover Patients for Community-Acquired Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia?
Current Respiratory Medicine Reviews Controlled and Continuous Release Ocular Drug Delivery Systems: Pros and Cons
Current Drug Delivery The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Bioactive Peptides - Are There More Antihypertensive Mechanisms Beyond ACE Inhibition?
Current Pharmaceutical Design The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Secondary Prevention of Atherothrombotic Cerebrovascular Events
Current Vascular Pharmacology Use of New Therapeutic Compounds in Pregnancy with Renal Disease
Current Women`s Health Reviews Tolvaptan: A New Therapeutic Agent
Reviews on Recent Clinical Trials